tailieunhanh - Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance. Methods: Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete response (CR) on BRAF and/or MEK inhibitors was analyzed using next generation sequencing (NGS) assay. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN